Tessera Therapeutics received up to $41.3 million from ARPA‑H to support its EMBODY program, which aims to develop in‑vivo CAR‑T approaches that engineer immune cells directly in patients. The award will finance research into delivery systems and in‑vivo reprogramming technologies intended to simplify manufacturing, enable redosing, and broaden patient access to CAR‑T‑like therapies. Tessera’s grant is part of a broader ARPA‑H push to fund in‑vivo cell and gene therapy platforms that reduce the complexity and cost of ex‑vivo manufacturing. The company will use the funding to scale preclinical work and accelerate translational studies that could feed into IND‑enabling programs. ARPA‑H’s support signals government backing for platform technologies that could alter the economics of cell therapy if safety and efficacy hurdles are cleared. Investors and competitors will track how Tessera leverages the award to de‑risk manufacturing and delivery challenges central to in‑vivo approaches.